Barclays PLC Inozyme Pharma, Inc. Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Barclays PLC holds 2,001 shares of INZY stock, worth $8,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,001

Previous 2,001 -0.0%

Holding current value

$8,004

Previous $8,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$0.82 - $4.0 $49,447 - $241,208	-60,302 Reduced 96.79%	2,001 $8,000
Q1 2025 May 15, 2025	SELL	$0.91 - $3.07 $26,691 - $90,046	-29,331 Reduced 32.01%	62,303 $56,000
Q4 2024 Feb 13, 2025	BUY	$2.48 - $5.54 $36,961 - $82,568	14,904 Added 19.42%	91,634 $254,000
Q3 2024 Nov 15, 2024	BUY	$4.31 - $6.0 $239,192 - $332,982	55,497 Added 261.37%	76,730 $401,000
Q2 2024 Aug 14, 2024	SELL	$4.33 - $7.31 $67,877 - $114,591	-15,676 Reduced 42.47%	21,233 $94,000
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $133,370 - $246,766	-32,215 Reduced 46.6%	36,909 $282,000
Q4 2023 Feb 15, 2024	BUY	$2.71 - $4.5 $162,339 - $269,568	59,904 Added 649.72%	69,124 $295,000
Q3 2023 Nov 07, 2023	SELL	$4.09 - $7.0 $4,028 - $6,895	-985 Reduced 9.65%	9,220 $39,000
Q2 2023 Aug 03, 2023	BUY	$4.93 - $6.74 $19,384 - $26,501	3,932 Added 62.68%	10,205 $56,000
Q4 2022 Feb 13, 2023	SELL	$1.05 - $2.82 $136 - $366	-130 Reduced 2.03%	6,273 $7,000
Q2 2022 Aug 12, 2022	SELL	$3.2 - $5.96 $7,478 - $13,928	-2,337 Reduced 26.74%	6,403 $31,000
Q1 2022 May 16, 2022	BUY	$3.87 - $7.55 $33,823 - $65,987	8,740 New	8,740 $36,000

Others Institutions Holding INZY

# of Institutions

Shares Held

51.9M

Call Options Held

162K

Put Options Held

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $161M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account